SCHEMBL2708995

SCHEMBL2708995

CCc1nc2cnc3ccccc3c2n1OC

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
PDE10A Q9Y233 1/20 0.40
TLR7 Q9NYK1 5/20 0.38
GPR3 P46089 1/20 0.38
PDPK1 O15530 1/20 0.37
HTT P42858 2/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 2/20 0.36
BRD4 O60885 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2708176 0.89 MEN1 (0.43) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL2707501 0.87 TLR7 (0.47) ALDH1A1TLR7LMNATSHR
SCHEMBL2707291 0.85 ALDH1A1 (0.40) KDM4EL3MBTL1ALDH1A1HPGDMEN1
SCHEMBL2682348 0.83 TLR7 (0.42) KDM4EL3MBTL1ALDH1A1HPGDMEN1
SCHEMBL2682714 0.79 KDM4E (0.42) KDM4EL3MBTL1ALDH1A1HPGDMEN1
SCHEMBL2707399 0.77 KDM4E (0.38) KDM4EALDH1A1HPGDMAPTPDE10A
SCHEMBL2707491 0.77 TLR7 (0.48) KDM4EALDH1A1HPGDKMT2ATLR7
SCHEMBL2706419 0.77 CYP1A2 (0.40) KDM4EALDH1A1HPGDTLR7GPR3
SCHEMBL2709438 0.77 KDM4E (0.40) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL1895853 0.76 TLR7 (0.53) MEN1KMT2APDE10ATLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1789042-B1 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2012-05-02 EP disclosed
US-7579359-B2 1-alkoxy 1H-imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-08-25 US disclosed
EP-1789042-A4 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2009-07-22 EP disclosed
US-20090005376-A1 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2009-01-01 US disclosed
EP-1789042-A2 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-30 EP disclosed
WO-2006028962-A2 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005376-A1 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases IL2, IL4, IRF3 KDM4E 2441/4885L3MBTL1 3623/4885ALDH1A1 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.